Related by context. All words. (Click for frequent words.) 64 OLEPTRO TM 62 Abstral 61 Preotact 60 Loramyc R 60 RELISTOR 60 LUVOX CR 60 Pennsaid 60 SYCREST 59 Sancuso 59 ONSOLIS 59 alvimopan 59 Rectogesic 58 NEBIDO 58 PREOS R 58 LIALDA 58 Fortigel 58 BENLYSTA 58 Sanctura 57 Metformin GR 57 Flutiform TM 57 Relistor 57 Preotact R 57 BEMA Fentanyl 57 paliperidone palmitate 57 Lodotra 57 Civacir 57 Frova ® 57 Fortical R 57 Loramyc 57 FIRAZYR 57 Frova R 57 Exalgo 57 FOSRENOL 56 Marketing Authorization Application MAA 56 Nebido 56 silodosin 56 Gabapentin GR 56 Biologics License Application 56 Cellegesic 56 THALOMID 56 ONTAK 56 ZALBIN 56 granulated mesalamine 56 Onco TCS 56 Raptiva R 56 Intermezzo R 56 MONOVISC 56 Luvox CR 56 Opana ER 56 Dyloject 56 Mutual Recognition Procedure 56 CIP TRAMADOL ER 56 mometasone furoate 56 ATryn ® 55 Oracea 55 Onsolis 55 AzaSite 55 Plenaxis TM 55 ABILIFY R 55 Raptiva ® 55 Rapinyl 55 Vitaros 55 Extended Release Capsules 55 GEM #S 55 apaziquone 55 oral calcitonin 55 BYDUREON 55 PhosLo 55 Zelrix 55 methylnaltrexone 55 Enablex 55 Fanapt TM 54 Somatuline R Autogel R 54 Qutenza 54 Joulferon 54 Pennsaid R 54 ELAPRASE 54 Nitoman 54 Alvesco R 54 IV acetaminophen 54 TRANSDUR Sufentanil 54 Ruconest 54 Indaflex TM 54 naproxen esomeprazole magnesium 54 ULTRASE 54 Marketing Authorisation Application 54 satraplatin 54 HFA MDI 54 Ventavis 54 NVA# 54 Marketing Authorization 54 JOULFERON 54 Release Tablets 54 NDA submission 54 AMRIX 54 Xyrem ® 54 Icatibant 54 Intermezzo ® 54 Phase III clinical trials 53 Omigard TM 53 PREOS 53 ZEGERID Capsules 53 transdermal patch 53 Nexavar ® 53 ATryn R 53 Zavesca r 53 Ciclesonide 53 Vimovo 53 Dyloject TM 53 regadenoson 53 OFIRMEV 53 RELISTOR ® 53 Lixisenatide 53 Emezine 53 intravenous acetaminophen 53 XIBROM 53 XiDay 53 Probuphine 53 Viviant 53 REPLAGAL 53 dalbavancin 53 DAYTRANA TM 53 Sanctura XR 53 SEROQUEL XR 53 Sumavel DosePro 53 Seroquel XR 53 morphine sulfate extended 53 New Drug Application 53 Amoxicillin PULSYS 53 Oracea ® 53 methylnaltrexone bromide 53 cinacalcet HCl 53 QAB# indacaterol 53 Vasovist 53 AeroLEF TM 52 Xolegel 52 PhosLo R 52 levocetirizine 52 Ereska 52 trospium 52 Marketing Authorization Application 52 VIVITROL ® 52 BYETTA ® 52 topical NSAID 52 Xibrom TM 52 Orphan Drug designation 52 Sycrest 52 Rhucin 52 nasal calcitonin product 52 PEG INTRON 52 acyclovir Lauriad R 52 Somatuline Depot 52 Velac 52 Zalbin 52 Extended Release Tablets 52 Febuxostat 52 AMITIZA R 52 Orazol 52 miconazole Lauriad ® 52 Abstral ® 52 Trelstar R 52 diabetic neuropathic pain 52 Rhucin ® 52 Marketing Authorisation Application MAA 52 VYVANSE 52 METOZOLV ODT 52 BROMDAY 52 Focalin XR ® 52 Biologics License Application BLA 52 lubiprostone 52 Augment Bone Graft 52 Silenor ® 52 Tramadol ER 52 sublingual tablets 52 Actemra tocilizumab 52 IV APAP 52 bazedoxifene 52 subcutaneous RELISTOR 52 XIAFLEX ® 52 ENTEREG ® 52 ORENCIA ® 52 FACTIVE R gemifloxacin 52 UPLYSO 51 Stavzor 51 BEMA TM Fentanyl 51 XIAFLEX 51 Amitiza 51 Enjuvia 51 ONGLYZA ™ 51 clofarabine 51 faropenem 51 ferumoxytol Injection 51 Sular formulation 51 SUMAVEL 51 Evamist TM 51 HCV protease inhibitor 51 ezogabine 51 Kristalose ® lactulose 51 Kuvan 51 Firazyr 51 zolpidem tartrate sublingual tablet 51 Flutiform 51 BRILINTA 51 Q#IR 51 tezampanel 51 Zingo TM 51 Adcirca 51 Fanapt ™ 51 Neurodex 51 Rhucin R 51 Cimzia ® 51 Daytrana ® 51 Orapred ODT 51 Evoltra 51 highly purified pasteurized 51 BEMA Buprenorphine 51 Bronchitol 51 zileuton CR 51 ELADUR 51 albinterferon alfa 2b 51 Zolpimist 51 Silenor ® doxepin 51 linaclotide 51 Firdapse 51 PRISTIQ 51 LEVADEX ™ 51 Renvela 51 Ketotransdel 51 Voraxaze 51 QNEXA 51 EOquin 51 Orphan Drug designations 51 Fodosine 51 Xyzal R 51 Milnacipran 51 ABILIFY ® 51 TAXUS Element Stent System 51 Ketotransdel TM 50 CDP# 50 ARCOXIA 50 Rescula 50 Levoleucovorin 50 vilazodone 50 Zenpep 50 Mepact 50 NitroMist TM 50 Trobalt 50 Nabi HB Intravenous 50 NOXAFIL 50 proprietary transdermal patch 50 CHMP recommendation 50 Cleviprex TM clevidipine 50 DC Bead 50 Phase III trials 50 ibuprofen Injection 50 Junovan 50 5 lipoxygenase inhibitor 50 ANDAs 50 CIP ISOTRETINOIN 50 MAA submission 50 Factive 50 Omigard 50 Requip XL 50 balsalazide tablet 50 Daytrana TM 50 AeroLEF 50 PDE4 inhibitor 50 novel trazodone formulation 50 Xenazine ® 50 Asmanex 50 Combunox 50 subcutaneous formulation 50 SILENOR TM 50 DPP4 inhibitor 50 sevelamer carbonate 50 Clolar 50 SNT MC# 50 sBLA 50 OLpur TM H2H 50 taliglucerase alfa 50 Augment Injectable 50 Acetavance TM 50 Orally Disintegrating Tablets 50 Biologic License Application BLA 50 Cefprozil 50 forodesine 50 TREANDA 49 Ranexa R 49 Exalgo TM 49 Soliris TM eculizumab 49 Clevudine 49 NUVIGIL 49 Phase IIb trial 49 octreotide acetate 49 ONCONASE 49 tetrabenazine 49 Zensana 49 Fentanyl Taifun 49 KALBITOR ® 49 fluvoxamine maleate 49 Onalta 49 Cobalt Pharmaceuticals 49 NESINA 49 Jevtana 49 teduglutide 49 Oracea TM 49 Sucampo 49 supplemental biologics 49 fidaxomicin 49 gabapentin enacarbil 49 faropenem medoxomil 49 Acetavance 49 miconazole Lauriad R 49 Neupro ® 49 Trexima 49 Aryplase 49 Satraplatin 49 pivotal Phase III 49 Cladribine Tablets 49 indiplon capsules 49 acyclovir Lauriad ® 49 subcutaneously administered 49 StaphVAX 49 XIAFLEX ™ 49 Entereg 49 eprodisate KIACTA TM 49 LEUKINE 49 T Pred 49 ITAX 49 serotonin norepinephrine reuptake inhibitor 49 Phase III clinical 49 Ceplene 49 eltrombopag 49 Ketotransdel ® 49 NUEDEXTA ™ 49 Pirfenidone 49 SUPPRELIN R LA 49 Bepreve 49 Nerve Targeting Drug 49 albiglutide 49 Iluvien 49 Renvela ® 49 LUCASSIN 49 oral ridaforolimus 49 Iloperidone 49 Simulect 49 Release Capsules 49 OMNARIS 49 BLA filing 49 OMNARIS HFA 49 confirmatory Phase III 49 Esbriet pirfenidone 49 ACOMPLIA R 49 novel bactericidal 49 BioGlue R 49 sNDA submission 49 Panzem R 48 ORENCIA R 48 NovaDel 48 Gestiva TM 48 RECOTHROM R 48 ketoprofen patch 48 EGRIFTA TM 48 ONSOLIS TM 48 octreotide implant 48 confirmatory Phase 3 48 Anturol TM 48 bicifadine 48 Ixempra 48 CIMZIA r 48 registrational 48 Investigational Device Exemption IDE 48 Soriatane 48 SILENOR ™ 48 torezolid phosphate 48 REMOXY ® 48 RSD# 48 iloperidone 48 orphan designation 48 Strativa 48 JAK inhibitor 48 Vilazodone 48 Telavancin 48 Orphan Drug status 48 Valtropin 48 hydrochloride tablets 48 GENERIC SILDENAFIL SOFT Generic 48 rasagiline tablets 48 StaphVAX R 48 Dalbavancin 48 Cimzia TM 48 Urocidin 48 Tesamorelin 48 NDA Submission 48 pegloticase 48 Ferumoxytol 48 Keppra ® levetiracetam 48 alogliptin 48 Corlux 48 Flutiform ™ 48 HZT 48 Ofirmev 48 Application MAA 48 Antegren 48 BLA submission 48 Dacogen 48 prodrug stimulant 48 ACUROX ® 48 VEGF Trap 48 Anturol ® 48 Soliris eculizumab 48 Neuromodulation System 48 solifenacin succinate 48 topical gel 48 Alzhemed TM 48 Phase IIIb clinical 48 EMBEDA ™ 48 Horizant 48 desvenlafaxine 48 oral methylnaltrexone 48 Solzira 48 ALVESCO R 48 gepirone ER 48 Aloxi Injection 48 velaglucerase alfa 48 Extended Release 48 Cinryze TM 48 Benazepril 48 Ramelteon 48 ANDA containing 48 Cutanea Life Sciences 48 TachoSil 48 NGX# 48 Inhalation Aerosol 48 CoFactor 48 sNDA 47 REMOXY R 47 Dexilant 47 NitroMist 47 orally administered 47 Acurox 47 pantoprazole sodium 47 Vernakalant 47 Testosterone Gel 47 LEVADEX TM 47 AzaSite Plus 47 ridaforolimus 47 POSIDUR TM 47 phase IIb clinical 47 DU #b 47 SILENOR 47 VALSTAR 47 RANK Ligand inhibitor 47 ecallantide 47 BEMA TM LA 47 ruxolitinib 47 Surfaxin LS 47 OMAPRO ™ 47 Zyflo 47 Orphan Therapeutics 47 LibiGel 47 MethyPatch 47 MNTX 47 Application BLA 47 VISICOL R 47 vinorelbine emulsion 47 Divalproex Sodium 47 liver resection surgeries 47 commercialize toremifene 47 Transdermal System 47 supplemental Biologics License Application 47 overactive bladder AA# 47 Iluvien ® 47 Aloxi ® 47 Biologics Licensing 47 injectable formulation 47 XOPENEX HFA MDI 47 Drug Submission 47 Keppra ® XR 47 Zorbtive TM 47 Femring ® 47 Dacogen injection 47 Exelbine 47 INCB# [002] 47 IPLEX 47 Marketing Authorization Applications 47 Anturol 47 Phase III pivotal 47 Phase 2b 47 Onrigin TM 47 Clinical Trial Application 47 Linjeta TM 47 IND submission 47 APF# 47 tiapamil 47 Solzira TM 47 Ceflatonin R 47 lomitapide 47 indiplon 47 AMITIZA ® 47 investigational 47 Phase III Clinical Trial 47 amifampridine phosphate 47 sterile lidocaine patch 47 Zenvia ™ 47 FUSILEV ® 47 Elagolix 47 MBP# [001] 47 BCX# 47 ceftobiprole 46 MOZOBIL 46 Marqibo 46 QRxPharma 46 Indiplon 46 Drug Eluting Stent System 46 Sanvar R 46 Morphine Sulfate 46 Phase 2b study 46 Ropinirole 46 Plicera 46 Orphan Drug 46 oral hydromorphone 46 Market Approval PMA 46 Panzem R NCD 46 vernakalant oral 46 Apricus Bio 46 Orphan Drug Designation 46 Glybera R 46 Ambrisentan 46 NDA resubmission 46 BENLYSTA ® 46 Biological License Application 46 FUSILEV 46 oral prodrug 46 phase IIb 46 formoterol fumarate 46 bifeprunox 46 FDA approvable letter 46 fostamatinib 46 pioglitazone HCl 46 peginesatide 46 Drug Applications ANDAs 46 Surgical Adhesive 46 TYGACIL 46 milnacipran 46 Pegloticase 46 Jerini 46 Cetrorelix 46 PHX# 46 diabetic peripheral neuropathic pain 46 Phase III Clinical Trials 46 Phase 2b clinical 46 GATTEX 46 IND Investigational New 46 OROS R Hydromorphone 46 phase IIa clinical 46 ZEVALIN ® 46 Preos 46 prGCD 46 ILUVIEN ® 46 Inhalation Solution 46 European Medicines Evaluation 46 Aurexis 46 mesylate tablets 46 SPARLON 46 oxymorphone ER 46 LUVENIQ 46 Lung Rx 46 Pivotal Phase III 46 refractory Hodgkin lymphoma 46 PRX # 46 Diabetic Macular Edema 45 Actonel ® 45 application sNDA 45 dextromethorphan quinidine 45 Evoltra R 45 NEBIDO R 45 Complete Response 45 Thelin TM 45 pseudobulbar affect PBA 45 Phase IIb clinical trials 45 ELADUR ™ 45 Kynapid 45 Premarket Approval PMA 45 LEVADEX 45 ADVEXIN 45 Kuvan TM sapropterin 45 Investigational Compound 45 Onrigin 45 generation purine nucleoside 45 Bazedoxifene 45 dirucotide 45 ANDA 45 Kuvan R 45 Orathecin 45 Oral Solution 45 Act PDUFA date 45 Dextofisopam 45 Fast Track designations 45 SinuNase TM 45 PLK1 SNALP 45 ALN PCS 45 investigational drug 45 severe hypercholesterolemia 45 KRYSTEXXA 45 Investigational Device Exemption 45 Announces Tentative Approval 45 elotuzumab 45 IONSYS TM 45 IIa trial 45 Metformin HCl 45 Acurox r Tablets 45 Xibrom QD 45 Zerenex 45 Octreolin 45 Initiates Phase III 45 MK #B 45 lucinactant 45 naproxcinod 45 Clofarabine 45 Saforis 45 ANDA submission 45 GLP toxicology studies 45 Phase IIa trial 45 Shionogi 45 ThermoDox ® 45 Zenvia 45 Phase IIa trials 45 Phase IIb 45 Market Authorization Application 45 Tezampanel 45 SUTENT ® 45 diarrhea predominant irritable 45 Kamada AAT 45 CHMP 45 post operative ileus 45 Emezine R 45 Risperidone Oral Solution 45 Troxatyl 45 inhaled formulation 44 Amigal 44 intravenous formulation 44 topical non steroidal 44 Lubiprostone 44 TRANSDUR ® 44 testosterone gel LibiGel 44 Luveniq 44 Bifeprunox 44 tafamidis 44 Trizytek 44 vinflunine 44 Riquent 44 INDs 44 Mylan Receives Approval 44 Pruvel 44 ZEGERID Powder 44 PROMUS Element Stent System 44 LibiGel ® 44 REVLIMID lenalidomide 44 vernakalant hydrochloride 44 ENRICH trial 44 Oral Suspension 44 vinorelbine tartrate 44 Itopride 44 EvaMist TM 44 intranasal formulation 44 SparVax TM 44 STEDESA 44 Durezol TM 44 investigational compound 44 Phase IIa 44 Orphan Drug Status 44 severe gastroparesis 44 Cloretazine R VNP#M 44 Oral Calcitonin 44 Firazyr ® 44 Fast Track designation 44 mesylate tablets approved 44 Proxinium TM 44 Mometasone Furoate 44 Phase IIb clinical 44 phase 2a 44 Xcytrin R 44 SinuNase ™ 44 Granted Orphan Drug 44 PrevOnco ™ 44 Phase III Trial 44 initiate Phase IIb 44 lorcaserin NDA 44 SUCCEED trial 44 TELINTRA 44 Horizant ™ 44 Nascobal Nasal Spray 44 phase IIa 44 atypical antipsychotic medication 44 Entereg R 44 Phase III 44 PMA submission 44 Testosterone MDTS ® 44 Promacta 44 Investigational 44 Abbott Laboratories Depakote 44 inhaled liposomal ciprofloxacin 44 Junovan TM 44 Phenoptin 44 registrational trial 44 ATPace 44 submit Biologics License 44 FDA Approvable Letter 44 ONCONASE R 44 Empatic TM 44 Personalized Immunotherapy 44 Auxilium Pharma 44 sNDAs 44 Biologic License Application 43 cell lymphoma CTCL 43 Amigal TM 43 mifamurtide 43 granted Ortec 43 Fast Track Status 43 ofatumumab HuMax CD# 43 Fibrillex TM 43 Topical Interferon Alpha 2b 43 PNP inhibitor 43 pralatrexate 43 Evoltra ® 43 MK #A [001] 43 PDUFA Date 43 sapropterin dihydrochloride 43 Ustekinumab 43 LymphoStat B TM 43 CRMD# 43 TRANSDUR TM Sufentanil 43 PDUFA date 43 BioMimetic 43 pancreatic insufficiency 43 Krystexxa 43 liprotamase 43 investigational humanized monoclonal antibody 43 License Application sBLA 43 Phase Ib study 43 Exocrine Pancreatic Insufficiency 43 post herpetic neuralgia PHN 43 EMBEDA 43 DDP# 43 Phase IIa clinical trials 43 mGluR5 negative 43 Files Investigational 43 PROVENGE ® 43 Phase 1b trial 43 Pixuvri 43 VALSTAR R 43 ACUROX 43 New Drug IND 43 Gencaro 43 markets HP Acthar 43 Oral Suspension #mg 43 GATTEX TM 43 tolevamer 43 Act PDUFA 43 ZEGERID Chewable Tablets 43 oral cladribine 43 pharmacokinetic studies 43 Genasense ® oblimersen 43 phase IIb trial 43 diquafosol tetrasodium 43 Tolvaptan 43 Dupuytren Contracture 43 Phase III Pivotal 43 Initiate Clinical Trial 43 Archexin 42 Submits Supplemental 42 Hematide ™ peginesatide 42 refractory APL 42 submitted Biologics License 42 Roflumilast 42 CEQ# 42 Impax ANDA 42 Phase IIb Trial 42 ANTEGREN 42 postherpetic neuralgia PHN 42 MHLW 42 POSIDUR TM ELADUR TM 42 FOLOTYN ® 42 generation PNP inhibitor 42 Avanafil 42 candidate Zentase 42 topical gel formulation 42 lexidronam injection 42 dirucotide MBP# 42 submitted supplemental Biologics 42 formerly LymphoStat B 42 Fast Track Designation 42 Zenvia TM 42 Product Monograph 42 JZP 6 42 vapreotide acetate 42 FDA Accepts 42 proprietary intravenous formulation 42 brentuximab 42 FDA Complete Response 42 Pivotal Phase 42 IND enabling 42 hypoparathyroidism 42 Onyx Pharma 42 Prolacria 42 reliever tramadol 42 CORLUX 42 aclidinium bromide 42 clinical trial 42 Priority Review 42 Phase IIa clinical 42 & JPRD 42 hoFH 42 Alogliptin 42 Genz # 42 approvable letters 42 Phase 2b trial 42 Entereg TM 42 Gel repository corticotropin injection 42 sNDA filing 42 Neurodex TM 42 Submits NDA 42 Lenocta TM 42 CINTREDEKIN BESUDOTOX 42 Phase IIB 42 diabetic peripheral neuropathic DPN 41 Uvidem 41 histone deacetylase HDAC inhibitor 41 LymphoStat B belimumab 41 Premarket Approval Application 41 Pivotal Trial 41 eprodisate Fibrillex TM 41 Submits Biologics License Application 41 treat male hypogonadism 41 Phase 2a clinical 41 Receives Approvable Letter 41 norepinephrine reuptake inhibitor 41 human C1 inhibitor 41 Arzerra ofatumumab 41 LUNESTA TM 41 tramiprosate ALZHEMED TM 41 Efficacy Results 41 Oporia 41 Phase Ia 41 Phase Ib 41 humanized anti 41 KRYSTEXXA TM 41 Prestara 41 telavancin NDA 41 Meets Primary Endpoint 41 ® decitabine 41 Premarket Approval 41 Theratechnologies submitted 41 Human Genetic Therapies 41 HP Acthar Gel repository 41 EpiCept 41 orphan drug 41 Phase IIb trials 41 BLOOM DM 41 Stavzor ™ 41 Phase 1a clinical 41 investigational atypical antipsychotic 41 Approvable letter 41 Celgene Thalomid 41 Receives Orphan Drug Designation 41 Phase 2a 41 postoperative ileus POI 41 Phase IIb Clinical Trial 41 Investigational Treatment 41 Prestara TM 41 ISO Vorin TM 41 tasimelteon 41 k premarket 41 ocular hypertension 40 Intermezzo ® NDA 40 virus HCV protease inhibitor 40 cutaneous T cell 40 FavId 40 Zenvia Phase III 40 Transcept Pharmaceuticals 40 Phase 2a trial 40 Phase 1b 40 refractory chronic lymphocytic 40 omeprazole sodium bicarbonate 40 Drug Application 40 Liprotamase 40 Velaglucerase Alfa 40 Aerosurf 40 ATPace TM 40 KRYSTEXXA TM pegloticase 40 NYSE Amex PTN 40 topically applied SEPA 40 Marketing Approval PMA 40 brand eszopiclone 40 initiate Phase Ib 40 Initiate Phase 40 corticotropin injection 40 Drug Submission NDS 40 DASISION 40 Phase 1b clinical 40 PIX# trial 40 Submits Response 40 Drug Application ANDA 40 GRAS notification 40 Functional Dyspepsia 40 ENZON 40 allosteric modulator PAM 39 IL# PE#QQR 39 depressive episodes associated 39 GALNS 39 PEG PAL 39 TSX SHQ 39 % uracil topical 39 L MTP PE 39 Vion Pharmaceuticals 39 palifosfamide 39 R Saizen R 39 Inc. NASDAQ HITK 39 pivotal Phase 39 LibiGel NDA 39 REMOXY NDA 39 XL# anticancer compounds 39 European Medicines Agency 39 FDA Approval 39 Friedreich Ataxia FRDA 39 exocrine pancreatic insufficiency 39 Humanitarian Device Exemption 39 non constipation irritable 39 carcinogenicity study 39 Fx #A 39 dihydrochloride Tablets 39 Guanilib 39 ADVEXIN p# therapy 39 Abbreviated New 39 LSE SHP NASDAQ SHPGY 39 Completes Patient Enrollment 38 Camvia 38 diabetic macular edema DME 38 Patient Enrollment 38 PDX pralatrexate 38 Drug Administration FDA Oncologic 38 IND 38 Tolevamer 38 non nucleoside inhibitor 38 approvable letter 38 Phase II 38 Approvable Letter 38 NasdaqGM NTEC today 38 cutaneous T 38 Initiates Phase II 38 Exelbine NDA 38 APF# NDA 38 NASDAQ SHPGY 38 Reloxin ® 38 DIFICID ™ 38 Submits Investigational 38 chronic idiopathic thrombocytopenic purpura 37 NASDAQ CXSP announced 37 Serdaxin ® 37 individualized cellular immunotherapy 37 dose escalation clinical 37 Contrave NDA 37 NASDAQ IMCL 37 initiate Phase 37 initiate Phase 1b 37 prokinetic agent 37 By JAMAAL ABDUL 37 Inc. NASDAQ AVNR 37 Study Evaluating 37 IND Application 37 pralatrexate injection folate analogue 37 Nasdaq VRTX 37 autologous cellular immunotherapy 36 carcinogenicity studies 36 Silenor NDA 36 NASDAQ BDSI 36 preclinical 36 Resubmission 36 multiple ascending dose 36 initiate Phase IIa 36 Phase 2b Trial 36 PMA Supplement 36 resubmission 35 Inc. Nasdaq SEPR 35 L DOS# 35 Phase 2a Trial 35 Inc. Nasdaq VVUS 35 nephropathic cystinosis cystinosis 35 Drug Administration FDA 34 Celsion Corporation 34 Complete Response letter 34 Palatin Technologies Inc. 33 Special Protocol Assessment 33 Supplemental Biologics License Application 33 Inc. OTCBB SYBD 32 Nasdaq DVAX 31 BLA 31 Complete Response Letter